These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 19762733)

  • 1. Malignant hyperthermia-like syndrome and carnitine palmitoyltransferase II deficiency with heterozygous R503C mutation.
    Hogan KJ; Vladutiu GD
    Anesth Analg; 2009 Oct; 109(4):1070-2. PubMed ID: 19762733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Atypical malignant hyperthermia. A higher incidence than expected].
    Herrero E; Casinello F; de Stefano J; Fernández-Guisasola J; Pérez-Gallardo A
    Rev Esp Anestesiol Reanim; 1996 Jan; 43(1):42-3. PubMed ID: 8851836
    [No Abstract]   [Full Text] [Related]  

  • 3. [Malignant hyperthermia].
    Bouhajja B; Haddad F; Ben Ammar MS
    Tunis Med; 2002 Jul; 80(7):395-401. PubMed ID: 12611349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mild variant of malignant hyperthermia following succinylcholine and halogenated agent exposure].
    Fernández-García V; Bermejo MA; Vázquez C; Pereda MJ; Altarriba JM; Alvarez E
    Rev Esp Anestesiol Reanim; 1995 Nov; 42(9):401-2. PubMed ID: 8584782
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe infantile type of carnitine palmitoyltransferase II (CPT II) deficiency due to homozygous R503C mutation.
    Spiegel R; Shaag A; Gutman A; Korman SH; Saada A; Elpeleg O; Shalev SA
    J Inherit Metab Dis; 2007 Apr; 30(2):266. PubMed ID: 17372854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel mutations associated with carnitine palmitoyltransferase II deficiency.
    Taggart RT; Smail D; Apolito C; Vladutiu GD
    Hum Mutat; 1999; 13(3):210-20. PubMed ID: 10090476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Malignant hyperthermia].
    Glahn KP
    Ugeskr Laeger; 2003 Apr; 165(17):1763-8. PubMed ID: 12768904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human malignant hyperthermia associated with desflurane anesthesia.
    Allen GC; Brubaker CL
    Anesth Analg; 1998 Jun; 86(6):1328-31. PubMed ID: 9620529
    [No Abstract]   [Full Text] [Related]  

  • 9. Malignant hyperthermia and muscular dystrophies.
    Gurnaney H; Brown A; Litman RS
    Anesth Analg; 2009 Oct; 109(4):1043-8. PubMed ID: 19762730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant hyperthermia.
    Rosenberg H; Davis M; James D; Pollock N; Stowell K
    Orphanet J Rare Dis; 2007 Apr; 2():21. PubMed ID: 17456235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No carnitine palmitoyltransferase deficiency in skeletal muscle in 18 malignant hyperthermia susceptible individuals.
    Wieser T; Kraft B; Kress HG
    Neuromuscul Disord; 2008 Jun; 18(6):471-4. PubMed ID: 18430572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant hyperthermia: how to spot it early.
    Haslego SS
    RN; 2002 Jul; 65(7):31-5; quiz 36. PubMed ID: 12136527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anesthesia in hereditary peripheral muscular disease].
    Islander G; Jungner M
    Lakartidningen; 2005 Feb 21-27; 102(8):566-71. PubMed ID: 15786909
    [No Abstract]   [Full Text] [Related]  

  • 14. Malignant hyperthermia: an OR emergency!
    Plast Surg Nurs; 2000; 20(4):222-6. PubMed ID: 12025057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of 16 new disease-causing mutations in the CPT2 gene resulting in carnitine palmitoyltransferase II deficiency.
    Isackson PJ; Bennett MJ; Vladutiu GD
    Mol Genet Metab; 2006 Dec; 89(4):323-31. PubMed ID: 16996287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel mutations in Spanish patients with muscle carnitine palmitoyltransferase II deficiency.
    Martín MA; Rubio JC; del Hoyo P; García A; Bustos F; Campos Y; Cabello A; Culebras JM; Arenas J
    Hum Mutat; 2000 Jun; 15(6):579-80. PubMed ID: 10862092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Volatile anesthetics and succinylcholine in cardiac ryanodine receptor defects.
    Swan H; Laitinen PJ; Toivonen L
    Anesth Analg; 2004 Aug; 99(2):435-7, table of contents. PubMed ID: 15271719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimate of the relative risk of succinylcholine for triggering malignant hyperthermia.
    Dexter F; Epstein RH; Wachtel RE; Rosenberg H
    Anesth Analg; 2013 Jan; 116(1):118-22. PubMed ID: 23223104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unexpected MH deaths without exposure to inhalation anesthetics in pediatric patients.
    Brandom BW; Muldoon SM
    Paediatr Anaesth; 2013 Sep; 23(9):851-4. PubMed ID: 23848295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant hyperthermia: a case report in Thai Anesthesia Incidents Study (THAI Study).
    Pulnitiporn A; Charuluxananan S; Inphum P; Kitsampanwong W
    J Med Assoc Thai; 2005 Nov; 88 Suppl 7():S149-52. PubMed ID: 16862689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.